A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Qilu Pharmaceutical Co., Ltd.
Eli Lilly and Company
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
Critical Outcome Technologies Inc.